ANGELICA

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

Ensayo de CytoMed Therapeutics Ltd en Cancer · Malignancy · Refractory Cancer · Relapsed Cancer (del registro, en inglés).

Más ensayos de: Cáncer.

Fase: Fase 1
Estado: Reclutando pacientes
Participantes: 12
Centros: 1
Fin del objetivo primario: nov 2025

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en nov 2024.

Qué mide

To determine a dose regimen and schedule of CTM-N2D at which no more than one patient out of up to six patients at the same dose level experience a CTM-N2D-related DLT (Within 8 weeks immediately after the start of study treatment) (del registro, en inglés)

Qué se prueba

Se prueba la terapia celular CTM-N2D, basada en celulas T gamma-delta modificadas para atacar el antigeno NKG2DL, con el objetivo de determinar la dosis optima y evaluar su seguridad y tolerabilidad, ademas de observar la respuesta tumoral de los pacientes.

Lo que dice el documentoThe objective of this clinical trial is to determine the optimal dose of CTM-N2D, and to investigate its safety and tolerability. The subjects of the clinical trial will also be investigated for their tumour response to CTM-N2D. CTM-N2D has undergone preclinical studies.

Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroCAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient. Then in the lab, an artificial protein - a Chimeric Antigen Receptor (CAR), is grafted on the surface of immune cells. The modified cells, which are readministered to the patient, have enhanced abilities to target and destroy cancers than unmodified immune cells. Currently approved CAR-T can only be used autologously. i.e. the patient will receive CAR-T treatment made from their own cells. This is because current CAR-T treatment uses αβ T cells - a type of immune cell which are largely non-transferable between individual human beings due to the high risk of Graft-versus-Host Disease. However, autologous CAR-T comes with many limitations. A lengthy, manufacturing process follows after the patient donates their own blood, accompanied by a high risk of manufacturing failure, which can be attributed to the cell quality from cancer patients undergoing stressful anti-cancer therapy. CytoMed Therapeutics pioneers a new CAR-T treatment (CTM-N2D) which may confer some benefit over current CAR-T treatment. CTM-N2D uses a subtype of immune cell -- γδ T cell. Secondly, the CAR on CTM-N2D targets a surface antigen called NKG2DL which are commonly present in many cancer. These two features may confer a safer product profile, of better quality and may be efficacious in cancers where previous CAR-T treatments has not. The phase I clinical trial of CTM-N2D will be conducted at the National University Hospital, Singapore. The objective of this clinical trial is to determine the optimal dose of CTM-N2D, and to investigate its safety and tolerability. The subjects of the clinical trial will also be investigated for their tumour response to CTM-N2D. CTM-N2D has undergone preclinical studies. Relevant data from other clinical trials are also used to infer the expected outcome, and strategies of management of this clinical trial. The institution's ethical review board must give its approval before the study may begin. An independent Data Safety Monitoring Board monitors the safety aspect of this trial.

Más ensayos de GDTC

Ensayo	Fase	Estado	Lectura de resultados
Adoptive Cell Transfer of…	Fase 1	Sin noticias del promotor	sep 2020 (prevista, ya pasada: sin actualizar en el registro)

Todos los de GDTC, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05302037), actualizada en nov 2024.